IMPACT: Taking insulin and a GLP-1 agonist significantly increases the
ability of achievement stable blood sugar levels
READ TIME: 2 mins
* 1. “Sanofi’s Soliqua combines an insulin with a GLP-1 agonist, and,
according to a new real-world study, delivering those two therapies
simultaneously is the way to go.” *
* 2. “Starting an insulin and a GLP-1 drug around the same time—ideally
within 30 days or less of one another—gave certain Type 2 diabetes patients
a significantly better shot at achieving blood sugar control than starting
them more than three months apart did, according to real-world evidence
presented Saturday at the virtual American Diabetes Association annual
meeting.” *
* 3. “But insulin stigma is not the only thing that’s been deterring
patients from starting two drugs at once.” *
* 4. “Patients also want to avoid the hassle of taking multiple
therapies—and that’s where Soliqua comes in.” *
* 5. “The drug, administered as a single daily injection, “has a huge
advantage” for patients who might benefit from simultaneous basal insulin
and GLP-1 therapy, Sorli said.” *
Source URL:
https://www.fiercepharma.com/pharma/ada-sanofi-bolsters-soliqua-real-world-data-showing-starting-insulin-glp-1-together-helps